224 related articles for article (PubMed ID: 38170178)
21. Enhanced interaction between SEC2 mutant and TCR Vβ induces MHC II-independent activation of T cells via PKCθ/NF-κB and IL-2R/STAT5 signaling pathways.
Fu X; Xu M; Song Y; Li Y; Zhang H; Zhang J; Zhang C
J Biol Chem; 2018 Dec; 293(51):19771-19784. PubMed ID: 30352872
[TBL] [Abstract][Full Text] [Related]
22. Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling.
Nikolova M; Musette P; Bagot M; Boumsell L; Bensussan A
Blood; 2002 Aug; 100(3):1019-25. PubMed ID: 12130517
[TBL] [Abstract][Full Text] [Related]
23. Bacterial proteins that mediate the association of a defined subset of T cell receptor:CD4 complexes with class II MHC.
Yagi J; Baron J; Buxser S; Janeway CA
J Immunol; 1990 Feb; 144(3):892-901. PubMed ID: 2136903
[TBL] [Abstract][Full Text] [Related]
24. Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
Martinez-Escala ME; Kuzel TM; Kaplan JB; Petrich A; Nardone B; Rosen ST; Guitart J
JAMA Oncol; 2016 Jun; 2(6):790-3. PubMed ID: 27054291
[TBL] [Abstract][Full Text] [Related]
25. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
[TBL] [Abstract][Full Text] [Related]
26. Staphylococcal exotoxins deliver activation signals to human T-cell clones via major histocompatibility complex class II molecules.
Spertini F; Spits H; Geha RS
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7533-7. PubMed ID: 1881894
[TBL] [Abstract][Full Text] [Related]
27.
Blümel E; Munir Ahmad S; Nastasi C; Willerslev-Olsen A; Gluud M; Fredholm S; Hu T; Surewaard BGJ; Lindahl LM; Fogh H; Koralov SB; Rahbek Gjerdrum LM; Clark RA; Iversen L; Krejsgaard T; Bonefeld CM; Geisler C; Becker JC; Woetmann A; Andersen MH; Buus TB; Ødum N
Oncoimmunology; 2020; 9(1):1751561. PubMed ID: 32363124
[No Abstract] [Full Text] [Related]
28. [Epidermotropic T cell lymphomas as models for tumor progression].
Bagot M; Bensussan A
Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
[TBL] [Abstract][Full Text] [Related]
29. New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.
Luna DE; Shinohara MM
Curr Hematol Malig Rep; 2023 Jun; 18(3):83-88. PubMed ID: 37017872
[TBL] [Abstract][Full Text] [Related]
30. Doxycycline is an NF-κB inhibitor that induces apoptotic cell death in malignant T-cells.
Alexander-Savino CV; Hayden MS; Richardson C; Zhao J; Poligone B
Oncotarget; 2016 Nov; 7(46):75954-75967. PubMed ID: 27732942
[TBL] [Abstract][Full Text] [Related]
31. Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.
Krejsgaard T; Willerslev-Olsen A; Lindahl LM; Bonefeld CM; Koralov SB; Geisler C; Wasik MA; Gniadecki R; Kilian M; Iversen L; Woetmann A; Odum N
Blood; 2014 Jul; 124(5):761-70. PubMed ID: 24957145
[TBL] [Abstract][Full Text] [Related]
32. Major histocompatibility complex independent clonal T cell anergy by direct interaction of Staphylococcus aureus enterotoxin B with the T cell antigen receptor.
Hewitt CR; Lamb JR; Hayball J; Hill M; Owen MJ; O'Hehir RE
J Exp Med; 1992 Jun; 175(6):1493-9. PubMed ID: 1588277
[TBL] [Abstract][Full Text] [Related]
33. Mitigation strategies among cutaneous T-cell lymphoma patients with positive
Allen PB; Goyal S; Switchenko J; Tarabadkar E; Pouch S; Parikh P; Palmer A; Martini D; Kim E; Lechowicz MJ
Leuk Lymphoma; 2023 Mar; 64(3):597-604. PubMed ID: 35673767
[TBL] [Abstract][Full Text] [Related]
34. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
35. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
36. Novel therapeutic approaches for cutaneous T cell lymphomas.
Pavlidis A; Piperi C; Papadavid E
Expert Rev Clin Immunol; 2021 Jun; 17(6):629-641. PubMed ID: 33890833
[No Abstract] [Full Text] [Related]
37. Pathogenesis of cutaneous T cell lymphoma: Involvement of Staphylococcus aureus.
Fujii K
J Dermatol; 2022 Feb; 49(2):202-209. PubMed ID: 34927279
[TBL] [Abstract][Full Text] [Related]
38. Immunological study on CD3 defective cutaneous T cell lymphoma cells from a patient with Sézary syndrome.
Sano S; Matsui Y; Itami S; Yoshikawa K
Clin Exp Immunol; 1998 Aug; 113(2):190-7. PubMed ID: 9717967
[TBL] [Abstract][Full Text] [Related]
39. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.
Dohlsten M; Hedlund G; Akerblom E; Lando PA; Kalland T
Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9287-91. PubMed ID: 1924393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
